Oruka Therapeutics, Inc. Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Oruka Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2025.
  • Oruka Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$30.3M, a 5.78% decline year-over-year.
  • Oruka Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$107M, a 97.7% decline year-over-year.
  • Oruka Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$83.7M, a 1468% decline from 2023.
  • Oruka Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$5.34M, a 46.2% increase from 2022.
  • Oruka Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$9.93M, a 48.6% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Oruka Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$107M -$30.3M -$1.65M -5.78% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-12
Q2 2025 -$105M -$24.6M -$2.33M -10.5% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-11
Q1 2025 -$103M -$21M -$19M -945% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q4 2024 -$83.7M -$30.8M -$29.8M -2733% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-06
Q3 2024 -$54M -$28.6M -$27.2M -1910% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-12
Q2 2024 -$26.8M -$22.2M -$20.8M -1403% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-11
Q1 2024 -$6M -$2.01M -$663K -49.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-01
Q4 2023 -$5.34M -$1.09M +$85K +7.24% Oct 1, 2023 Dec 31, 2023 10-Q 2024-08-01
Q3 2023 -$5.42M -$1.42M +$909K +39% Jul 1, 2023 Sep 30, 2023 10-Q 2024-08-01
Q2 2023 -$6.33M -$1.48M +$1.67M +53% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$8M -$1.35M +$1.93M +58.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-01
Q4 2022 -$9.93M -$1.17M +$4.5M +79.3% Oct 1, 2022 Dec 31, 2022 10-Q 2023-10-18
Q3 2022 -$14.4M -$2.33M +$2.38M +50.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-18
Q2 2022 -$16.8M -$3.15M +$1.69M +34.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-10-18
Q1 2022 -$18.5M -$3.27M +$828K +20.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-10-18
Q4 2021 -$19.3M -$5.68M -$551K -10.8% Oct 1, 2021 Dec 31, 2021 10-Q 2022-10-28
Q3 2021 -$18.8M -$4.71M -$2.72M -137% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-28
Q2 2021 -$16.1M -$4.83M -$3.53M -271% Apr 1, 2021 Jun 30, 2021 10-Q 2022-10-28
Q1 2021 -$12.5M -$4.1M -$2.78M -211% Jan 1, 2021 Mar 31, 2021 10-Q 2022-10-28
Q4 2020 -$9.74M -$5.13M -$3.9M -318% Oct 1, 2020 Dec 31, 2020 10-Q 2021-11-02
Q3 2020 -$5.84M -$1.99M -$835K -72.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 -$5M -$1.3M +$134K +9.33% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-02
Q1 2020 -$5.14M -$1.32M +$344K +20.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-02
Q4 2019 -$5.48M -$1.23M +$263K +17.7% Oct 1, 2019 Dec 31, 2019 10-Q 2020-11-02
Q3 2019 -$5.75M -$1.16M +$437K +27.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-02
Q2 2019 -$6.18M -$1.44M +$680K +32.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-02
Q1 2019 -$6.86M -$1.66M +$1.07M +39.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-02
Q4 2018 -$7.93M -$1.49M +$2.71M +64.5% Oct 1, 2018 Dec 31, 2018 10-Q 2019-11-06
Q3 2018 -$10.6M -$1.59M +$2.84M +64.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 -$13.5M -$2.12M +$3.41M +61.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-06
Q1 2018 -$16.9M -$2.74M +$1.6M +37% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-06
Q4 2017 -$18.5M -$4.2M +$47K +1.11% Oct 1, 2017 Dec 31, 2017 10-Q 2018-11-14
Q3 2017 -$18.5M -$4.43M +$226K +4.85% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 -$18.8M -$5.52M -$1.63M -41.8% Apr 1, 2017 Jun 30, 2017 10-Q 2018-11-14
Q1 2017 -$17.1M -$4.34M -$691K -18.9% Jan 1, 2017 Mar 31, 2017 10-Q 2018-11-14
Q4 2016 -$16.4M -$4.24M -$1.08M -34% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-22
Q3 2016 -$15.4M -$4.66M -$1.85M -65.6% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 -$13.5M -$3.89M -$1.18M -43.2% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 -$12.3M -$3.65M -$903K -32.9% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q4 2015 -$11.4M -$3.17M -$557K -21.3% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-21
Q3 2015 -$10.9M -$2.81M -$530K -23.2% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 -$10.4M -$2.72M -$314K -13.1% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 -$10M -$2.74M -$355K -14.9% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-11
Q4 2014 -$9.69M -$2.61M +$335K +11.4% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-17
Q3 2014 -$10M -$2.28M -$561K -32.6% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 -$9.46M -$2.41M -$1.21M -101% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-11
Q1 2014 -$8.26M -$2.39M -$1.32M -123% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-12
Q4 2013 -$6.94M -$2.95M -$2.11M -251% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-19
Q3 2013 -$4.83M -$1.72M -$796K -85.9% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-12
Q2 2013 -$4.04M -$1.2M -$53K -4.63% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-13
Q1 2013 -$3.98M -$1.07M +$336K +23.9% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-13
Q4 2012 -$4.32M -$840K +$790K +48.5% Oct 1, 2012 Dec 31, 2012 10-Q 2014-05-13
Q3 2012 -$5.11M -$927K +$895K +49.1% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-13
Q2 2012 -$6.01M -$1.15M -$1.44M -490% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-13
Q1 2012 -$4.57M -$1.41M +$799K +36.2% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-13
Q4 2011 -$5.36M -$1.63M Oct 1, 2011 Dec 31, 2011 10-Q 2014-05-13
Q3 2011 -$1.82M +$284K +13.5% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-13
Q2 2011 $294K +$2.56M Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-13
Q1 2011 -$2.21M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-14
Q3 2010 -$2.11M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
Q2 2010 -$2.27M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-15

Oruka Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$83.7M -$78.4M -1468% Feb 6, 2024 Dec 31, 2024 10-K 2025-03-06
2023 -$5.34M +$4.59M +46.2% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-01
2022 -$9.93M +$9.4M +48.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-01
2021 -$19.3M -$9.58M -98.4% Jan 1, 2021 Dec 31, 2021 10-K 2023-02-24
2020 -$9.74M -$4.26M -77.6% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-14
2019 -$5.48M +$2.45M +30.9% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-18
2018 -$7.93M +$10.6M +57.1% Jan 1, 2018 Dec 31, 2018 10-K 2020-02-18
2017 -$18.5M -$2.05M -12.4% Jan 1, 2017 Dec 31, 2017 10-K 2019-02-27
2016 -$16.4M -$5M -43.7% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-22
2015 -$11.4M -$1.76M -18.1% Jan 1, 2015 Dec 31, 2015 10-K 2017-03-21
2014 -$9.69M -$2.75M -39.6% Jan 1, 2014 Dec 31, 2014 10-K 2016-03-17
2013 -$6.94M -$2.62M -60.6% Jan 1, 2013 Dec 31, 2013 10-K 2015-03-19
2012 -$4.32M +$1.04M +19.5% Jan 1, 2012 Dec 31, 2012 10-Q 2014-05-13
2011 -$5.36M +$3.06M +36.3% Jan 1, 2011 Dec 31, 2011 10-Q 2014-05-13
2010 -$8.42M Jan 1, 2010 Dec 31, 2010 10-Q 2014-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.